Topiramate
Eprontia, Qsymia, Qudexy, Topamax, Topiramate, Trokendi (topiramate) is a small molecule pharmaceutical. Topiramate was first approved as Topamax on 1996-12-24. It is used to treat bipolar disorder, epilepsy, infantile spasms, lennox gastaut syndrome, and pain amongst others in the USA. It is known to target carbonic anhydrase 7, carbonic anhydrase 12, carbonic anhydrase 4, and carbonic anhydrase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Eprontia, Qudexy, Topamax, Topiramate, Trokendi (discontinued: Topamax, Topiramate)
CombinationsPhentermine topiramate, Qsymia
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Topiramate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EPRONTIA | Azurity | N-214679 RX | 2021-11-05 | 1 products, RLD, RS |
| TOPAMAX | Johnson & Johnson | N-020505 RX | 1996-12-24 | 4 products, RLD |
| TOPAMAX | Johnson & Johnson | N-020844 RX | 1998-10-26 | 2 products, RLD, RS |
| TROKENDI XR | Supernus Pharmaceuticals | N-201635 RX | 2013-08-16 | 4 products, RLD, RS |
| QUDEXY XR | Upsher-Smith Laboratories | N-205122 RX | 2014-03-11 | 5 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| eprontia | New Drug Application | 2024-05-17 |
| qsymia | New Drug Application | 2024-10-03 |
| qudexy | New Drug Application | 2024-08-05 |
| topamax | New Drug Application | 2023-05-12 |
| topiramate | ANDA | 2024-10-30 |
| topiramate tablets | 2009-04-03 | |
| topiramate topiramate | ANDA | 2016-05-19 |
| trokendi xr | New Drug Application | 2024-10-10 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PHENTERMINE HYDROCHLORIDE / TOPIRAMATE, QSYMIA, VIVUS | |||
| 2025-06-24 | NPP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Topiramate, Eprontia, Azurity | |||
| 11433046 | 2040-08-21 | U-3413, U-3414, U-3415 | |
| 11633374 | 2040-08-21 | DP | |
| Topiramate, Qudexy Xr, Upsher Smith Labs | |||
| 8652527 | 2033-03-19 | DP | |
| 8889190 | 2033-03-19 | DP | |
| 9101545 | 2033-03-19 | DP | |
| 9555005 | 2033-03-19 | DP | |
| 10363224 | 2033-03-19 | U-766 | |
| Phentermine Hydrochloride / Topiramate, Qsymia, Vivus | |||
| 8580299 | 2029-06-14 | U-3399 | |
| 8580298 | 2029-05-15 | DP | |
| 8895057 | 2028-06-09 | U-3398 | |
| 8895058 | 2028-06-09 | DP | |
| 9011905 | 2028-06-09 | DP | |
| 9011906 | 2028-06-09 | U-3398 | |
| Topiramate, Trokendi Xr, Supernus Pharms | |||
| 8298576 | 2028-04-04 | DP | U-106, U-1992 |
| 8298580 | 2027-11-16 | DP | U-106, U-1992 |
| 8663683 | 2027-11-16 | DP | U-106, U-1992 |
| 8877248 | 2027-11-16 | DP | U-106, U-1992 |
| 8889191 | 2027-11-16 | U-106, U-1992 | |
| 8992989 | 2027-11-16 | DP | U-1675, U-1992 |
| 9549940 | 2027-11-16 | DP | U-1675, U-1992 |
| 9555004 | 2027-11-16 | DP | U-1675, U-1992 |
| 9622983 | 2027-11-16 | DP | U-1675, U-1992 |
| 10314790 | 2027-11-16 | DP | U-1675, U-1992 |
HCPCS
No data
Clinical
Clinical Trials
322 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 5 | 7 | 20 | 16 | 17 | 64 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 7 | 8 | 16 | 15 | 13 | 57 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 3 | 15 | 17 | 14 | 9 | 57 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 2 | 14 | 8 | 8 | 2 | 30 |
| Seizures | D012640 | HP_0002069 | G40.4 | 1 | 5 | 15 | 3 | 3 | 27 |
| Headache | D006261 | HP_0002315 | R51 | — | 2 | 7 | 4 | 6 | 19 |
| Partial epilepsies | D004828 | EFO_0004263 | — | — | 5 | 5 | 4 | — | 14 |
| Syndrome | D013577 | — | — | — | 1 | 6 | 3 | 2 | 12 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 4 | 6 | 1 | 1 | 12 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 2 | — | 5 | 5 | — | 12 |
Show 63 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | — | F14 | 1 | 5 | 3 | — | 1 | 9 |
| Feeding and eating disorders | D001068 | — | F50 | 2 | 2 | 2 | — | 2 | 7 |
| Binge-eating disorder | D056912 | — | F50.2 | 1 | 3 | 2 | — | 2 | 7 |
| Morbid obesity | D009767 | EFO_0001074 | — | — | 4 | 1 | — | — | 5 |
| Psychotic disorders | D011618 | — | F20.81 | 1 | — | 2 | — | 1 | 4 |
| Tobacco use disorder | D014029 | — | F17 | — | 3 | 2 | — | — | 4 |
| Gambling | D005715 | EFO_1001926 | F63.0 | — | 2 | 1 | — | — | 3 |
| Lennox gastaut syndrome | D065768 | — | G40.81 | — | — | 2 | — | 1 | 3 |
| Spasm | D013035 | — | M62.83 | — | 1 | 1 | — | 1 | 2 |
| Sclerosis | D012598 | — | — | — | 1 | 1 | — | — | 2 |
Show 29 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 11 | 1 | — | — | 2 | 14 |
| Central nervous system neoplasms | D016543 | — | — | 1 | 2 | — | — | — | 2 |
| Nervous system neoplasms | D009423 | — | — | 1 | 2 | — | — | — | 2 |
| Dyskinesias | D020820 | HP_0002310 | G24 | — | 2 | — | — | — | 2 |
| Addictive behavior | D016739 | EFO_0004347 | — | — | 1 | — | — | 1 | 2 |
| Alcoholic intoxication | D000435 | — | — | — | 2 | — | — | — | 2 |
| Bariatric surgery | D050110 | — | — | — | 2 | — | — | — | 2 |
| Ischemia | D007511 | EFO_0000556 | — | 1 | 2 | — | — | — | 2 |
| Hypoxia | D000860 | HP_0012418 | R09.02 | 1 | 2 | — | — | — | 2 |
| Brain diseases | D001927 | HP_0001298 | G93.40 | 1 | 2 | — | — | — | 2 |
Show 37 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | 1 | 3 |
| Postoperative pain | D010149 | — | G89.18 | 1 | — | — | — | — | 1 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | — | — | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acidosis | D000138 | EFO_1000014 | E87.2 | — | — | — | — | 2 | 2 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | — | — | — | — | 1 | 1 |
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | — | — | — | — | 1 | 1 |
| Synovitis | D013585 | EFO_0008997 | M67.5 | — | — | — | — | 1 | 1 |
| Radiculopathy | D011843 | — | M54.1 | — | — | — | — | 1 | 1 |
| Gout | D006073 | EFO_0004274 | M10 | — | — | — | — | 1 | 1 |
| Rett syndrome | D015518 | Orphanet_778 | F84.2 | — | — | — | — | 1 | 1 |
| Financial stress | D000086522 | — | — | — | — | — | — | 1 | 1 |
| Metabolic bone diseases | D001851 | HP_0000938 | — | — | — | — | — | 1 | 1 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | — | — | — | — | 1 | 1 |
Show 16 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Topiramate |
| INN | topiramate |
| Description | Topiramate is a hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine. It has a role as an anticonvulsant and a sodium channel blocker. It is a cyclic ketal, a sulfamate ester and a ketohexose derivative. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1 |
Identifiers
| PDB | — |
| CAS-ID | 97240-79-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL220492 |
| ChEBI ID | 63631 |
| PubChem CID | 5284627 |
| DrugBank | DB00273 |
| UNII ID | 0H73WJJ391 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
No data
Financial
Revenue by drug
$
€
ÂŁ
â‚Ł
Trokendi – Supernus Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Qsymia – Vivus
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Topiramate
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 18,188 documents
View more details
Safety
Black-box Warning
Black-box warning for: Qudexy
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
42,297 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use